SCHEMBL11370367

SCHEMBL11370367

Cc1cccc(-c2nc3cc(S(=O)(=O)Nc4ccc(F)cc4F)ccc3[nH]2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.48
TP53 P04637 3/20 0.48
LMNA P02545 4/20 0.43
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
KIT P10721 2/20 0.42
HSD11B1 P28845 1/20 0.41
MOGAT2 Q3SYC2 1/20 0.41
GHSR Q92847 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
MAPK1 P28482 2/20 0.39
GAA P10253 1/20 0.39
GLO1 Q04760 1/20 0.39
NTSR1 P30989 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6925826 0.90 MAPT (0.49) MAPTTP53LMNAKMT2AMEN1
SCHEMBL6927666 0.85 CBFB (0.54) MAPTTP53LMNAKMT2AMEN1
SCHEMBL11370588 0.83 MAPT (0.52) MAPTTP53LMNAKMT2AMEN1
SCHEMBL6926524 0.83 MAPT (0.68) MAPTTP53LMNAKMT2AMEN1
SCHEMBL6926267 0.77 MAPT (0.51) MAPTTP53LMNAKMT2AMEN1
SCHEMBL6926224 0.77 MAPT (0.46) MAPTTP53LMNAMOGAT2GLO1
SCHEMBL11369844 0.77 MAPT (0.46) MAPTTP53LMNAKMT2AMEN1
SCHEMBL6926724 0.76 CBFB (0.55) MAPTTP53LMNAKMT2AMEN1
SCHEMBL6925491 0.75 GRM4 (0.51) MAPTTP53LMNAKMT2AMEN1
SCHEMBL6926782 0.73 MAPT (0.66) MAPTTP53LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS GRM4, GRIK4, GRIA4 MAPT 3868/4885TP53 4875/4885LMNA 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.